Showing 15 posts of 89 posts found.


Discovery of predictive protein signature births new leukaemia treatment hopes

April 12, 2017
Research and Development leukaemia

Researchers have discovered a protein signature which has proven to be highly predictive of leukaemia and has given rise to …


Scotland recommends Janssen’s Imbruvica for leukaemia

April 11, 2017
Manufacturing and Production, Sales and Marketing SMC, imbruvica, leukaemia

Janssen has been celebrating the news that its Imbruvica (ibrutinib) has been recommended by the Scottish Medicines Consortium (SMC) for …


Novartis investigational CAR-T therapy gets FDA priority review

March 30, 2017
Sales and Marketing CTL019, FDA, Novartis, leukaemia

Novartis’ investigational chimeric antigen receptor T cell (CAR-T) therapy CTL019 (tisagenlecleucel-T) has been awarded has been awarded priority review by …


Link discovered between immune system genes and leukaemia

February 6, 2017
Research and Development, Sales and Marketing Bloodwise, ICR, leukaemia

Research coming out of The Institute of Cancer Research, and funded by charity Bloodwise, has found that people who inherit …


Phase 2 failure for Innate Pharma leukaemia drug

February 6, 2017
Research and Development, Sales and Marketing Innate Pharma, leukaemia, lirilumab

Lirilumab, Innate Pharma’s acute myeloid leukaemia (AML) treatment, has failed to meet its primary end point in a recent Phase …

Personalised leukaemia vaccine shows promise in new trial

December 12, 2016
Sales and Marketing leukaemia

A personalised cancer vaccine has proven to have significant efficacy in the treatment of acute myeloid leukaemia (AML), researchers at …


Novartis posts 82% remission rate in CAR T paediatric study

December 5, 2016
Research and Development, Sales and Marketing CAR T, CAR-T, Novartis, leukaemia, paediatric

Novartis has released the results of its global, paediatric study of the treatment of leukaemia in children and young adults …


Teva’s drug to replace chemotherapy in acute leukaemia

November 21, 2016
Medical Communications, Sales and Marketing Teva, chemotherapy, first line, first-line, leukaemia

Teva Pharmaceutical announced that their drug Trisenox has been given approval from the European Commission to become the first line …


Nordic Nanovector to collaborate with Heidelberg Pharma to develop leukaemia treatment

October 26, 2016
Research and Development Nordic Nanovector, WILEX, heidelberg pharma, leukaemia

Nordic Nanovector has announced that they have formed a partnership with WILEX subsidiary, Heidelberg Pharma. Heidelberg Pharma specialises in the …

New treatment for leukaemia nullifies cancer cells

October 13, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Boston, Cancer, Germany, Harvard, Mainz University, leukaemia

New research was able to demonstrate that a targeted drug-based inactivation of two chromatin regulators would interrupt the self-renewal of …

Gamida Cell receives Breakthrough Therapy Designation from FDA

October 12, 2016
Research and Development Breakthrough Therapy Designation, FDA, Gamida Cell, leukaemia, lymphoma

Gamida Cell have been granted a Breakthrough Therapy Designation for their NiCord drug. NiCord has already passed through Phase I …


Amgen’s leukaemia treatment given FDA thumbs up for use in paediatric patients

September 2, 2016
Medical Communications, Sales and Marketing Amgen, FDA, blincyto, leukaemia

Amgen has announced that the FDA has approved the supplemental Biologics License Application for Blincyto (blinatumomab) in the treatment of …

Jazz Pharmaceuticals to acquire Celator in $1.5 billion deal

May 31, 2016
Manufacturing and Production, Sales and Marketing $1.5 billion, Vyxeos, acquisition, celator, jazz, leukaemia, merger, oncology

Jazz Pharmaceuticals (NASDAQ: JAZZ) has announced that it has entered into a definitive merger agreement with Celator Pharmaceuticals (NASDAQ: CPXX) …


Incyte acquires Ariad’s European operations in $140 million deal

May 10, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Ariad, Incyte, Operations, buy out, european, iclusig, leukaemia, out-license

Incyte (NASDAQ: INCY) has entered into an agreement with Ariad Pharmaceuticals (NASDAQ: ARIA) that will see the company acquire Ariad’s …

Latest content